explore -WSS

explore

author：focus 2025-09-30 23:39:30 - browse：1

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

WSS

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Some top drug companies are starting to take action on climate

Nobel honors Karikó and Weissman's enduring partnership

How Vertex's cystic fibrosis drug is changing patients' lives

Medical student insurance fails on mental health care coverage

Second xenotransplant done with gene

leisure time

explore

hotspot

In Memoriam: Notable people who died in 2023

How Vertex's cystic fibrosis drug is changing patients' lives

Activists slam private health insurers over coverage restrictions

CDC's new outbreak response network to include Northeastern

Drug repurposing or repositioning? The language matters

Senators: Long

Medicare proposal to cover medical devices draws a mixed reaction

Biotech lab space demand falls sharply

Continuity nursing helped my family in our darkest PICU moments

Medicare innovation center doesn’t save money, experts say

Wikipedia

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Some top drug companies are starting to take action on climate

How AI helped researchers track recovery from depression

CDC picks Alphabet's Verily for wasterwater surveillance contract

Study points to new risk in gene therapy death of Terry Horgan

Readout LOUD podcast: possible new ALS drug, artificial wombs

leisure time

focus

focus

hotspot